Rescue of Fatal Neonatal Hemorrhage in Factor V Deficient Mice by Low Level Transgene Expression

Tony L. Yang; Jisong Cui; Jeremy M. Taylor; Angela Yang; Stephen B. Gruber; David Ginsburg

doi:10.1055/s-0037-1613760

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2000; 83(01): 70-77
DOI: 10.1055/s-0037-1613760

Commentary

Schattauer GmbH

Rescue of Fatal Neonatal Hemorrhage in Factor V Deficient Mice by Low Level Transgene Expression

Tony L. Yang

¹From the Department of Human Genetics, University of Michigan

,

Jisong Cui

²Howard Hughes Medical Institute

³Merck & Co., Inc., Rahway, NJ

,

Jeremy M. Taylor

⁴Department of Biostatistics, University of Michigan, Ann Arbor, MI

,

Angela Yang

²Howard Hughes Medical Institute

,

Stephen B. Gruber

⁵Department of Internal Medicine, University of Michigan

⁶Department of Epidemiology, University of Michigan, USA

,

David Ginsburg

¹From the Department of Human Genetics, University of Michigan

²Howard Hughes Medical Institute

⁵Department of Internal Medicine, University of Michigan

› Institutsangaben

Abstract

Summary

Factor V (FV) is a critical component of the coagulation cascade. FV-deficient patients suffer moderate to severe bleeding, though residual FV activity is detectable in nearly all cases. In contrast, FVdeficient mice die either during mid-embryogenesis, or of massive perinatal hemorrhage. In order to examine the requirements for FV in murine embryogenesis and hemostasis, we generated transgenic mouse lines expressing a Fv minigene under control of either the tissue-specific albumin (Malb) or rat platelet factor 4 (Rpf4) promoter. A total of 12 Malb and 3 Rpf4 lines were analyzed. Though expression in the target tissue was detectable in most lines by RT-PCR, only low levels of transgene expression were achieved (<3% of endogenous Fv in all lines). Despite a low level of Fv transgene expression, rescue of the lethal Fv ^−/− phenotype was observed with one of the Malb transgenic (Tg+) lines. However, rescue appeared to be incomplete with continued loss of >¹/2 of expected Tg+, Fv ^−/− mice in early embryogenesis. Rescued Tg+, Fv ^−/− mice have undetectable FV (<0.1%) in both plasma and platelet compartments, but survive the perinatal period and mature to adulthood without spontaneous hemorrhage. We conclude that FV present at <0.1% is sufficient to support postnatal survival. Failure of the Malb transgene to rescue the midembryonic block suggests that FV expression is required during mammalian development at higher levels or with a different tissue-specific or temporal pattern. Taken together, these data may explain the observation of residual FV activity in most human FV-deficient patients due to early embryonic lethality in those absolutely deficient, and suggest that minimal levels of FV expression, below the level of detection, also may be sufficient to support survival in humans.

Keywords

Transgenic - mice - factor V

Volltext

Referenzen

References
1 Kane WH, Majerus PW. Purification and characterization of human coagulation factor V. J Biol Chem 1981; 256: 1002-7.
2 Suzuki K, Dahlbäck B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem 1982; 257: 6556-64.
3 Nesheim ME, Taswell JR, Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. J Biol Chem 1979; 254: 10952-62.
4 Rosing J, Tans G. Coagulation factor V: an old star shines again. Thromb Haemost 1997; 78: 427-33.
5 Tracy PB, Eide LL, Bowie EJW, Mann KG. Radioimmunoassay of Factor V in human plasma and platelets. Blood 1982; 60: 59-63.
6 Kane WH, Davie EW. Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin. Proc Nat Acad Sci, USA 1986; 83: 6800-4.
7 Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM. et al. Complete cDNA and derived amino acid sequence of human factor V. Proc Nat Acad Sci, USA 1987; 84: 4845-50.
8 Kane WH, Ichinose A, Hagen FS, Davie EW. Cloning of cDNAs coding for the heavy chain region and connecting region of human factor V, a blood coagulation factor with four types of internal repeats. Biochemistry 1987; 26: 6508-14.
9 Camire RM, Pollak ES, Kaushansky K, Tracy PB. Secretable human platelet-derived factor V originates from the plasma pool. Blood 1998; 92: 3035-41.
10 Chiu HC, Schick PK, Colman RW. Biosynthesis of factor V in isolated guinea pig megakaryocytes. J Clin Invest 1985; 75: 339-46.
11 George JN. Platelet immunoglobulin G: Its significance for the evaluation of thrombocytopenia and for understanding the origin of α-granule proteins. Blood 1990; 76: 859-70.
12 Gewirtz AM, Shapiro C, Shen YM, Boyd R, Colman RW. Cellular and molecular regulation of factor V expression in human megakaryocytes. J Cell Physiol 1992; 153: 277-87.
13 Borchgrevink CF, Owren PA. The hemostatic effect of normal platelets in hemophilia and factor V deficiency. Acta Med Scand 1961; 170: 375-83.
14 Nesheim ME, Nichols WL, Cole TL, Houston JG, Schenk RB, Mann KG. et al. Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 1986; 77: 405-15.
15 Yang TL, Cui J, Rehumtulla A, Yang A, Moussalli MJ, Kaufman RJ. et al. The structure and function of murine factor V and its inactivation of protein C. Blood 1998; 91: 4593-9.
16 Pinkert CA, Ornitz DM, Brinster RL, Palmiter RD. An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. Genes & Development 1987; 01: 268-76.
17 Ravid K, Beeler DL, Rabin MS, Ruley HE, Rosenberg RD. Selective targeting of gene products with the megakaryocyte platelet factor 4 promoter. Proc Nat Acad Sci, USA 1991; 88: 1521-5.
18 Izban MG, Papaconstantinou J. Cell-specific expression of mouse albumin promoter. J Bio Chem 1989; 264: 9171-9.
19 Camper SA, Tilghman SM. Postnatal repression of the α-fetoprotein gene is enhancer independent. Genes & Development 1989; 03: 537-46.
20 Ravid K, Doi T, Beeler DL, Kuter DJ, Rosenberg RD. Transcriptional regulation of the rat platelet factor 4 gene: interaction between an enhancer/silencer domain and the GATA site. Mol Cell Biol 1991; 11: 6116-27.
21 Hogan B, Beddington R, Constantini F, Lacy E. Manipulating the mouse embryo, a laboratory manual. 2nd ed. Plainview, NY: Cold Spring Harbor Laboratory Press; 1994
22 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
23 Nichols WC, Lyons SE, Harrison JS, Cody RL, Ginsburg D. Severe von Willebrand disease due to a defect at the level of von Willebrand factor mRNA expression: detection by exonic PCR-restriction fragment length polymorphism analysis. Proc Nat Acad Sci, USA 1991; 88: 3857-61.
24 Cui J, O’Shea KS, Purkayastha A, Saunders TL, Ginsburg D. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature 1996; 384: 66-8.
25 Heckel JL, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 1990; 62: 447-56.
26 Thompson A, Zhang Y, Kamen D, Jackson CW, Cardiff RD, Ravid K. Deregulated expression of c-myc in megakaryocytes of transgenic mice increases megakaryopoiesis and decreases polyploidization. J Biol Chem 1996; 271: 22976-82.
27 Wight DC, Wagner TE. Transgenic mice: a decade of progress in technology and research. Mutation Research 1994; 307: 429-40.
28 Henikoff S. Conspiracy of silence among repeated transgenes. Bioassays 1998; 20: 532-5.
29 Ong K, Horsfall W, Conway EM, Schuh AC. Early embryonic expression of coagulation system components during murine development. Blood 1998; 92 10 Suppl 1 188a.
30 Cascio S, Zaret KS. Hepatocyte differentiation initiates during endodermalmesenchymal interactions prior to liver formation. Development 1991; 113: 217-25.
31 Bugge TH, Xiao Q, Kombrinck KW, Flick MJ, Holmbäck K, Danton MJS. et al. Fatal embryonic bleeding events in mice lacking tissue factor, the cellassociated initiator of blood coagulation. Proc Nat Acad Sci, USA 1996; 93: 6258-63.
32 Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I. et al. Role of tissue factor in embryonic blood vessels development. Nature 1996; 383: 73-5.
33 Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze Jr GJ. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996; 88: 1583-7.
34 Connolly AJ, Ishihara H, Kahn ML, Farese Jr RV, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature 1996; 381: 516-9.
35 Darrow AL, Fung-Leung W-P, Ye RD, Santulli RJ, Cheung W-F, Derian CK. et al. Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost 1996; 76: 860-6.
36 Sun WY, Witte DP, Degen JL, Colbert MC, Burkart MC, Holmbäck K. et al. Prothrombin deficiency results in embryonic and neonatal lethality in mice. Proc Nat Acad Sci, USA 1998; 95: 7597-602.
37 Xue J, Wu Q, Westfield LA, Tuley EA, Lu D, Zhang Q. et al. Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice. Proc Nat Acad Sci, USA 1998; 95: 7603-7.
38 Suh TT, Holmbäck K, Jensen NJ, Daugherty CC, Small K, Simon DI. et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes & Development 1995; 09: 2020-33.
39 Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian Jr HH. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nature Genetics 1995; 10: 119-21.
40 Wang L, Zoppè M, Hackeng TM, Griffin JH, Lee K-F, Verma IM. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Nat Acad Sci, USA 1997; 94: 11563-6.
41 Lin H-F, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997; 90: 3962-6.
42 Kundu RK, Sangiorgi F, Wu LY, Kurachi K, Anderson WF, Maxson R. et al. Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. Blood 1998; 91: 168-74.
43 Gailani D, Lasky NM, Broze Jr GJ. A murine model of factor XI deficiency. Blood Coagulation and Fibrinolysis 1997; 08: 134-44.
44 Theiler K. The House Mouse. New York: Springer-Verlag; 1989
45 Roberts HR, Lefkowitz JB. Inheritied Disorders of Prothrombin Conversion. In: Colman RW, Hirsh J, Marder VJ, Salzman EW. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadelphia: J. B. Lippincott Co; 1994: 200-18.
46 Seeler RA. Parahemophilia. Medical Clinics of North America 1972; 56: 119-25.
47 Tracy PB, Mann KG. Abnormal formation of the prothrombinase complex: factor V deficiency and related disorders. Hum Pathol 1987; 18: 162-9.
48 Guasch JF, Cannegieter S, Reitsma PH, Van’t Veer-Korthof ET, Bertina RM. Severe coagulation factor V deficiency caused by a 4 bp deletion in the factor V gene. Bri J Haematol 1998; 101: 32-9.
49 Cooper DN, Millar DS, Wacey A, Pemberton S, Tuddenham EGD. Inherited factor X deficiency: molecular genetics and pathphysiology. Thromb Haemost 1997; 78: 161-72.
50 Antonarakis SE, Kazazian HH, Tuddenham EGD. Molecular etiology of factor VIII deficiency in Hemophilia A. Human Mutation 1995; 05: 1-22.
51 Giannelli F, Green PM, Sommer SS, Poon M-C, Ludwig M, Schwaab R. et al. Haemophilia B: database of point mutations and short additions and deletions, 7th edition. Nucleic Acids Research 1997; 25: 133-5.
52 Pugh RE, McVey JH, Tuddenham EGD, Hancock JF. Six point mutations that cause factor XI deficiency. Blood 1995; 85: 1509-16.
53 Neeman-Arbez M, Honsberger A, Antonarakis SE, Morris MA. Deletion of the fibrinogen alpha-chain gene (FGA) causes congenital afibrinogenemia. J Clin Invest 1999; 103: 215-8.
54 Owren PA. Parahæmophilia, hæmorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet 1947; 01: 446-8.
55 Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992; 31: 3777-85.
56 Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH. et al. Characterization of the human factor VIII gene. Nature 1984; 312: 326-30.
57 Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Ann Rev Biochem 1988; 57: 915-56.
58 Murray JM, Rand MD, Egan JO, Murphy S, Kim HC, Mann KG. Factor V_{New Brunswick}: Ala₂₂₁-to-Val substitution results in reduced cofactor activity. Blood 1995; 86: 1820-7.
59 Lunghi B, Castoldi E, Mingozzi F, Bernardi F. A novel factor V null mutation detected in a thrombophilic patient with pseudo-homozygous APC resistance and in an asymptomatic unrelated subject. Blood 1998; 92: 1463-4.
60 Zehnder JL, Hiraki D, Jones C, Gross N, Grumet FC. Familial coagulation factor V deficiency caused by a novel 4 base pair insertion in the factor V gene. Blood 1998; 92 10, Suppl. 1 354a-355a.
61 Young M, Inaba H, Hoyer LW, Higuchi M, Kazazian Jr HH, Antonarakis SE. Partial correction of a severe molecular defect in hemophilia A because of errors during expression of the factor VIII gene. Am J Hum Genet 1997; 60: 565-73.
62 Hu PY, Waheed A, Sly WS. Partial rescue of human carbonic anhydrase II frameshift mutation by ribosomal frameshift. Proc Nat Acad Sci, USA 1995; 92: 2136-40.
63 Keller FG, Ortel TL, Quinn-Allen MA, Kane WH. Thrombin-catalyzed activation of recombinant human factor V. Biochemistry 1995; 34: 4118-24.
64 Klein CJ, Coovert DD, Bulman DE, Ray PN, Mendell JR, Burghes AH. Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Gen 1992; 50: 950-9.
65 Wilton SD, Dye DE, Laing NG. Dystrophin gene transcripts skipping the mdx mutation. Muscle & Nerve 1997; 20: 728-34.